TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The purpose of this study is to evaluate the efficacy and safety of TACE in combination with Camrelizumab and Apatinib versus TACE in patients with intermediate- and advanced HCC.
Epistemonikos ID: 734b6392cf00653f115b0ca14c01798ba0388bf4
First added on: May 07, 2024